These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 5994826)

  • 21. [Reaction of the human granulopoiesis to large doses of cyclophosphamide].
    Lohrmann HP; Schreml W; Heimpel H
    Verh Dtsch Ges Inn Med; 1978; (84):600-4. PubMed ID: 742082
    [No Abstract]   [Full Text] [Related]  

  • 22. [Compatibility and action of very high dosage of endoxuan in the treatment of tumors].
    Martini H; Scheef W; Knecht B
    Med Welt; 1967 Jul; 26():1573-8. PubMed ID: 5616188
    [No Abstract]   [Full Text] [Related]  

  • 23. [Modification of hematotoxic effects of cyclophosphamide by anabolid steroids].
    Fölsch E; Brügger W; Brands W
    Arzneimittelforschung; 1975 Jan; 25(1):59-66. PubMed ID: 1173770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Side effects of ionizing irradiation and cyclophosphamide administration as well as modification of these disorders].
    Schmidt W
    Zentralbl Gynakol; 1969 Nov; 91(47):1537-40. PubMed ID: 5408544
    [No Abstract]   [Full Text] [Related]  

  • 25. Residual marrow damage following therapy with cyclophosphamide.
    Fried W; Barone J
    Exp Hematol; 1980 May; 8(5):610-4. PubMed ID: 7007067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of single-dose vincristine, actinomycin D, and cyclophosphamide in childhood solid tumors.
    Green DM
    Cancer Treat Rep; 1978 Oct; 62(10):1517-20. PubMed ID: 709553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy of autologous preserved marrow on patients undergoing myelodepressive therapeutic treatment].
    Polese E; Massenti S; Rossi-Torelli M
    Minerva Med; 1970 Sep; 61(77):4159-62. PubMed ID: 4921987
    [No Abstract]   [Full Text] [Related]  

  • 28. [Course of hematotoxic cyclophosphamide effects in the rat].
    Werner W; Haller M; Höpfner V; Küchler J; Ziervogel J
    Exp Pathol (Jena); 1971; 5(1):123-7. PubMed ID: 5098036
    [No Abstract]   [Full Text] [Related]  

  • 29. [Hemoprotection with dicarbamine: shielding of bone marrow hemopoietic cells from apoptosis and induction of cell differentiation in myelosuppressive effect of cyclophosphamide].
    Raĭkhlin NT; Bukaeva IA; Sitdikova SM; Nebol'sin VE
    Vopr Onkol; 2011; 57(4):497-500. PubMed ID: 22191241
    [No Abstract]   [Full Text] [Related]  

  • 30. [The protective action of a thymus extract on hematopoiesis in patients treated with intense radiation and cytostatic therapy].
    Orecchia C; Ardizzone L; Sigaudo F
    Minerva Med; 1970 Sep; 61(72):3825-36. PubMed ID: 5454451
    [No Abstract]   [Full Text] [Related]  

  • 31. The effects of combined administration of cytembena and cyclophosphamide on the blood count and morphology of nucleoli in peripheral-blood lymphocytes in patients with malignant tumors.
    Matĕjková E
    Neoplasma; 1975; 22(1):45-54. PubMed ID: 1173938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [First clinical experiences with ultrahigh single doses of cyclophosphamide].
    Schmitz G; Gross R
    Med Welt; 1967 Apr; 16():985-9. PubMed ID: 5585096
    [No Abstract]   [Full Text] [Related]  

  • 33. [Long-term consequences of the damaging effect of cytostatic drugs on hematopoiesis and lymphoid tissue].
    Gol'dberg ED; Novitskiĭ VV; Zapuskalova OB; Klimova MIu
    Vestn Akad Med Nauk SSSR; 1990; (9):52-7. PubMed ID: 2264389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Chemotherapy of malignant tumors using massive-dose administration of Endoxan].
    Pigatto JC
    Munch Med Wochenschr; 1967 Oct; 109(40):2082-4. PubMed ID: 4873942
    [No Abstract]   [Full Text] [Related]  

  • 35. High-dose cyclophosphamide (NSC-26271) for the treatment of metastatic testicular neoplasms.
    Buckner CD; Clift RA; Fefer A; Funk DD; Glucksberg H; Neiman PE; Paulsen A; Storb R; Thomas ED
    Cancer Chemother Rep; 1974; 58(5 Pt 1):709-14. PubMed ID: 4609599
    [No Abstract]   [Full Text] [Related]  

  • 36. [The effect of intraoperative massive dose therapy on the postoperative condition].
    Schmidt D
    Wien Med Wochenschr; 1969 Jan; 119(1):15-8. PubMed ID: 5773406
    [No Abstract]   [Full Text] [Related]  

  • 37. High-dose cyclophosphamide (NSC-26271) therapy in childhood acute leukemia.
    Steuber CP; Fernbach DJ; Starling KA; Falletta JM
    Cancer Chemother Rep; 1974; 58(3):417-9. PubMed ID: 4601672
    [No Abstract]   [Full Text] [Related]  

  • 38. Intermittent high-dose cyclophosphamide (NSC-26271) treatment of stage III ovarian carcinoma.
    Buckner CD; Briggs R; Clift RA; Fefer A; Funk DD; Glucksberg H; Neiman PE; Storb R; Thomas ED
    Cancer Chemother Rep; 1974; 58(5 Pt 1):697-703. PubMed ID: 4426048
    [No Abstract]   [Full Text] [Related]  

  • 39. [Autologous stem cell harvesting after high dosage chemo- and/or growth factor therapy].
    Kasparu H; Krieger O; Bettelheim P; Kolb A; Lutz D
    Wien Med Wochenschr; 1995; 145(2-3):58-60. PubMed ID: 7539197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [On tolerance of high dosage intraoperative cytostatic prophylaxis in cancer].
    Schmidt D; Haym J; Schuh D
    Dtsch Gesundheitsw; 1967 Oct; 22(43):2025-30. PubMed ID: 5600191
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.